Global Bioprocess Automation Software Market Size Likely to Grow at a CAGR of 14% By 2035

The market size of the global bioprocess automation software will be estimated at USD 1.67 billion in 2025 and is expected to grow to between USD 1.90 billion in 2026 and about USD 6.19 billion by 2035 with a current CAGR of 14% during the period of 2026 to 2035.

Bioprocess Automation Software Market Revenue and Trends

Bioprocess automation software for the biopharma sector is the top-of-the-line, multi-purpose software for monitoring, controlling, integrating, and producing biological manufacturing processes digitally. Mainly the software is designed for the biopharmaceutical industry, but it can also be used in the biotechnology field. In fact, such software manages the whole spectrum of the most critical operations — both upstream and downstream, including cell culture, fermentation, purification, and formulation.

The reason why the software can do that is because of real-time data collection, automated process control, and centralized data management. With the help of bioprocess automation software, product quality remains stable, operational efficiency gets better, manual intervention is lessened, and compliance with regulatory standards (like Good Manufacturing Practices—GMP) is assured. Besides, the software provides monitoring of advanced analytics, process modeling, and digital connectivity; thus, the platforms are crucial in setting up massive, dependable, and data-driven biomanufacturing environments.

What are the Factors That Have a Significant Contribution to the Growth of the Bioprocess Automation Software Market?

The primary factor influencing the bioprocess automation software market is the shift towards personalized medicine, among several others. The workflows that lead to these medications must be extremely flexible, accurate, and most importantly, data-oriented. Some personalized medicines are cell and gene therapies, as well as patient-specific biologics, which consist of small, highly variable batches generally. This kind of production forbids the use of traditional manual or rigid methods of production processes. Bioprocess automation software provides the capability to rapidly switch the process, perform real-time monitoring, and have digital workflows that are uniform, thereby assuring the same quality and consistency even with frequent changeovers. However, automation platforms provide support for traceability, electronic batch records, and compliance, all of which are crucial when dealing with individualized treatments. Demand for progressive bioprocess automation software is also rising as healthcare systems slowly embrace precision and personalized therapies.

Additionally, modular and scalable manufacturing methods are the main ones pushing the bioprocess automation software market, as the flexibility for biopharmaceutical production to adapt rapidly to the changing requirements and amounts of products is what these companies want. The modular buildings usually are made of single-use and standardized systems; therefore, they need very good automation software that will connect the equipment, supervise the workflows, and maintain the same level of control over the processes in all the modules.

Bioprocess automation software makes it possible to quickly scale up or down operations, to manufacture several products at the same time, and to transfer processes between locations in a quality-preserving way. Besides, scalable software platforms are a great help for the manufacturers in the areas of resource optimization, capital cost reduction, and time-to-market acceleration. The modular and scalable approaches are one of the reasons why advanced bioprocess automation software is heavily relied upon as the industry moves towards producing in a flexible, cost-effective, and future-proof manner.

Segment Insight

By End Use

The pharmaceutical & biotech manufacturers segment is expected to dominate the market over the projected period. The necessity of enhancing productivity, keeping the same level of product quality, and complying with very strict regulations puts the pressure on these businesses, while automation software is the best solution for handling complex bioprocessing workflows in an efficient manner. By the integration of systems such as MES, LIMS, and PAT, the manufacturers are able to watch the processes as they happen and improve the process using the data and all this with the human errors being reduced to a minimum.

Regional Insights

The bioprocess automation software market has been dominated by North America. The robust healthcare infrastructure, significant R&D investment, and the presence of top biopharmaceutical companies are the backbone of the regional development. The area has been characterized by the utilization of automation technology, which has been driven by the established supply networks and the ongoing focus on precision medicine and the production of cell and gene therapies. The demand for bioprocess solutions that are effective, scalable, and compliant will be the key factor in revenue generation in the coming years as the aging population and the incidence of diseases continue to rise.

Besides, the Asia Pacific market has the highest rate of growth in the bioprocess automation software market. The advent of industry 4.0 is a major factor driving the industry growth in the region over the projected period.

Report Scope

Recent Developments

• In January 2026, Insilico Medicine, an AI-based drug discovery company that is one of the best in the world, declared a long-term research and development (R&D) collaboration with Servier, the international pharmaceutical company that is independent and based in France. The cooperation intends to discover and create new cancer therapies that are targeting hard-to-drug spots by utilizing Insilico's Pharmaceutical AI platform. The R&D will thus combine the best of AI into the earlier phases of drug research—a trend that has started to catch on among the pharmaceutical manufacturers. This is particularly true in the case of cancer, where there still are large unmet medical needs. (Source: https://www.drugtargetreview.com/news/192003/insilico-secures-888million-servier-partnership-for-ai-oncology/)

List of the prominent players in the Bioprocess Automation Software Market:

• Xeris Pharmaceuticals Inc.

• Teva Pharmaceuticals USA Inc.

• Novo Nordisk A/S

• Sun Pharmaceutical Industries Ltd.

• Recordati

• Debiopharm

• Novartis Pharmaceuticals Corporation

• Ipsen Biopharmaceuticals Canada Inc.

• Crinetics Pharmaceuticals Inc.

• Ionis Pharmaceuticals

• Camurus AB

• Pfizer Inc.

• Eppendorf SE

• Genedata AG

• Thermo Fisher Scientific Inc

• Sartorius AG

• Others

The Bioprocess Automation Software Market is segmented as follows:

By Type

• Distributed Control Systems

• Manufacturing Execution Systems

• Supervisory Control and Data Acquisition

• Laboratory Information Management Systems

• Process Analytical Technology

By Application

• Upstream Processing

• Quality Control

• Downstream Processing

• Data Management

• Manufacturing Operations

By End Use

• Pharmaceutical & Biotech Manufacturers

• Academic & Research Institutions

• CDMOs & CMOs

• Contract Testing & Analytical Labs

• Others

Regional Coverage:

North America

• U.S.

• Canada

• Mexico

• Rest of North America 

Europe

• Germany

• France

• U.K.

• Russia

• Italy

• Spain

• Netherlands

• Rest of Europe

Asia Pacific

• China

• Japan

• India

• New Zealand

• Australia

• South Korea

• Taiwan

• Rest of Asia Pacific 

The Middle East & Africa

• Saudi Arabia

• UAE

• Egypt

• Kuwait

• South Africa

• Rest of the Middle East & Africa

Latin America

• Brazil

• Argentina

• Rest of Latin America